---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-23-002239"
form_type: "8-K"
ticker: "TGTX"
cik: "0001001316"
company_name: "TG THERAPEUTICS, INC."
filed_at: "2023-02-28T23:59:59+00:00"
generated_at: "2026-06-18T19:49:06.760941+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# TG Therapeutics reports Q4 2022 net loss of $53M; launches BRIUMVI for RMS

## Summary
- Net loss of $53.0M for Q4 2022, compared to $93.3M loss in Q4 2021; full year net loss $198.3M vs $348.1M.
- Product revenue net $2.6M for full year 2022 from UKONIQ (withdrawn May 2022); no BRIUMVI revenue yet.
- Cash and investments $174.1M at Dec 31, 2022; plus $45M available under term loan; runway into mid-2024.
- FDA approved BRIUMVI for RMS in 2022; commercial launch began early 2023; early feedback encouraging.
- R&D expense decreased to $29.6M in Q4 2022 from $62.6M in Q4 2021; SG&A decreased to $22.5M from $32.4M.

## SEC filing metadata
- accession: 0001558370-23-002239
- form_type: 8-K
- ticker: TGTX
- cik: 0001001316
- company_name: TG THERAPEUTICS, INC.
- filed_at: 2023-02-28T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1001316/000155837023002239/0001558370-23-002239-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1001316/000155837023002239/tgtx-20230228x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-23-002239
- JSON: https://secwatch.observer/filing/0001558370-23-002239.json
- Plain text: https://secwatch.observer/filing/0001558370-23-002239.txt

## Key facts
- Earnings Releases
  TG THERAPEUTICS, INC. reported the three months ended December 31, 2022 results: revenue approximately zero, net income $53.0 million.
  - Period: the three months ended December 31, 2022
  - Revenue: approximately zero
  - Net income: $53.0 million
  - Result: reported results
  source text: Product Revenue, net: Product revenue, net was approximately zero and $2.6 million for the three and twelve months ended December 31, 2022. Net product revenues during the year represent U.S. sales of UKONIQ, which received approval in February of 2021 and was withdrawn from the U.S. market effective May 31, 2022. · R&D Expenses: Total research and development (R&D) expense was $29.6 million and $125.4 million for the three and twelve months ended December 31, 2022, compared to $62.6 million and $222.6 million for the three and twelve months ended December 31, 2021. The decrease in R&D expense is primarily attributable to reduced clinical trial related expenses, license milestones and manufacturing expense, decreased headcount and lower fees paid to consultants and outside service providers, as well as a decrease in non-cash compensation R&D expense during the twelve months ended December 31, 2022 over the comparable period in 2021. · SG&A Expenses: Total selling, general and administr
  evidence_url: https://www.sec.gov/Archives/edgar/data/1001316/000155837023002239/0001558370-23-002239-index.htm
- Earnings Releases
  TG THERAPEUTICS, INC. reported the twelve months ended December 31, 2022 results: revenue $2.6 million, net income $198.3 million.
  - Period: the twelve months ended December 31, 2022
  - Revenue: $2.6 million
  - Net income: $198.3 million
  - Result: reported results
  source text: Product Revenue, net: Product revenue, net was approximately zero and $2.6 million for the three and twelve months ended December 31, 2022. Net product revenues during the year represent U.S. sales of UKONIQ, which received approval in February of 2021 and was withdrawn from the U.S. market effective May 31, 2022. · R&D Expenses: Total research and development (R&D) expense was $29.6 million and $125.4 million for the three and twelve months ended December 31, 2022, compared to $62.6 million and $222.6 million for the three and twelve months ended December 31, 2021. The decrease in R&D expense is primarily attributable to reduced clinical trial related expenses, license milestones and manufacturing expense, decreased headcount and lower fees paid to consultants and outside service providers, as well as a decrease in non-cash compensation R&D expense during the twelve months ended December 31, 2022 over the comparable period in 2021. · SG&A Expenses: Total selling, general and administr
  evidence_url: https://www.sec.gov/Archives/edgar/data/1001316/000155837023002239/0001558370-23-002239-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.